Other formats:
BibTeX
LaTeX
RIS
@article{1378057,
author = {Veselka, Josef and Jensen, Morten Kvistholm and Liebregts, Max and Januska, Jaroslav and Krejčí, Jan and Bartel, Thomas and Dabrowski, Maciej and Hansen, Peter Riis and Bundgaard, Henning and Steggerda, Robbert and Faber, Lothar},
article_location = {Clare},
article_number = {"neuvedeno"},
doi = {http://dx.doi.org/10.1016/j.ijcard.2016.02.077},
keywords = {HYPERTROPHIC CARDIOMYOPATHY; TASK-FORCE; GUIDELINES; DIAGNOSIS; MYECTOMY},
language = {eng},
issn = {0167-5273},
journal = {International Journal of Cardiology},
title = {Low procedure-related mortality achieved with alcohol septal ablation in European patients},
volume = {209},
year = {2016}
}
TY - JOUR
ID - 1378057
AU - Veselka, Josef - Jensen, Morten Kvistholm - Liebregts, Max - Januska, Jaroslav - Krejčí, Jan - Bartel, Thomas - Dabrowski, Maciej - Hansen, Peter Riis - Bundgaard, Henning - Steggerda, Robbert - Faber, Lothar
PY - 2016
TI - Low procedure-related mortality achieved with alcohol septal ablation in European patients
JF - International Journal of Cardiology
VL - 209
IS - "neuvedeno"
SP - 194-195
EP - 194-195
PB - Elsevier Ireland Ltd.
SN - 01675273
KW - HYPERTROPHIC CARDIOMYOPATHY
KW - TASK-FORCE
KW - GUIDELINES
KW - DIAGNOSIS
KW - MYECTOMY
N2 - Two thirds of patients with hypertrophic cardiomyopathy (HCM) suffer from a left ventricular obstruction associated with more symptoms and worse prognosis [1] ; [2]. According to American and European Guidelines on HCM, there are two main therapeutic alternatives for treating the left ventricular obstruction: surgical myectomy and alcohol septal ablation (ASA) [1] ; [2]. Both these alternatives are considered safe and effective. However, Panaich et al. have recently demonstrated real world American data from the Nationwide Inpatient Sample (NIS) database showing an almost 6% in-hospital mortality rate associated with surgical myectomy [3]. This study is important because it contradicts lower, previously established post-operative mortality rates, which were estimated to be ~ 1% and were calculated using data from high-volume centers. Importantly, however, current guidelines on HCM have been based only on results of these high-volume centers [1] ; [2]. Along this line, Maron et al. recently found that in five major high-volume HCM centers in North America, the 30-day operative mortality rate was only 0.4% over the past 15 years (n = 3.696, mean age 54 ± 14 years) [4], i.e., one fifteenth of mortality rate reported by Panaich et al. [3]. A recent meta-analysis of long-term outcomes after septal reduction therapy, including 24 studies from tertiary HCM centers around the world, showed that the peri-procedural mortality rate of ASA was 1.3%, compared to 2.5% in patients undergoing myectomy [5]. However, when studies from before the year 2000 were excluded, as Maron et al. suggest [4], these figures became similarly low (1.3% vs. 1.1%, respectively). The same held true for the long-term mortality rates.
ER -
VESELKA, Josef, Morten Kvistholm JENSEN, Max LIEBREGTS, Jaroslav JANUSKA, Jan KREJČÍ, Thomas BARTEL, Maciej DABROWSKI, Peter Riis HANSEN, Henning BUNDGAARD, Robbert STEGGERDA and Lothar FABER. Low procedure-related mortality achieved with alcohol septal ablation in European patients. \textit{International Journal of Cardiology}. Clare: Elsevier Ireland Ltd., 2016, vol.~209, ''neuvedeno'', p.~194-195. ISSN~0167-5273. Available from: https://dx.doi.org/10.1016/j.ijcard.2016.02.077.
|
